“We are extremely pleased to welcome David to the Histogenics’ Board of Directors,” said Adam Gridley, president and CEO of Histogenics. “David’s financial and industry expertise and experience make him an excellent choice for Histogenics as both a board member and Chairman of the Audit Committee.”
Mr. Gill joined EndoChoice as CFO in 2014. He has held the CFO position with a number of other organizations including INC Research and TransEnterix.
Histogenics focuses on regenerative medicine in the musculoskeletal marketplace.
More articles on gastroenterology:
5 must-reads for independent GI practices
8 gastroenterologist inventors
pCLE effective at diagnosing biliary cancer patients during ERCP, study says
